KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Biomarin Pharmaceutical (BMRN) Non-cash Items: 2010-2017

Historic Non-cash Items for Biomarin Pharmaceutical (BMRN) over the last 8 years, with Dec 2017 value amounting to $281.1 million.

  • Biomarin Pharmaceutical's Non-cash Items fell 97.82% to $6.6 million in Q4 2017 from the same period last year, while for Dec 2017 it was $6.6 million, marking a year-over-year decrease of 97.82%. This contributed to the annual value of $281.1 million for FY2017, which is 7.63% down from last year.
  • As of FY2017, Biomarin Pharmaceutical's Non-cash Items stood at $281.1 million, which was down 7.63% from $304.4 million recorded in FY2016.
  • Over the past 5 years, Biomarin Pharmaceutical's Non-cash Items peaked at $630.9 million during FY2015, and registered a low of $8.1 million during FY2014.
  • In the last 3 years, Biomarin Pharmaceutical's Non-cash Items had a median value of $304.4 million in 2016 and averaged $405.5 million.
  • As far as peak fluctuations go, Biomarin Pharmaceutical's Non-cash Items surged by 7,695.74% in 2015, and later crashed by 51.76% in 2016.
  • Over the past 5 years, Biomarin Pharmaceutical's Non-cash Items (Yearly) stood at $8.4 million in 2013, then fell by 3.59% to $8.1 million in 2014, then skyrocketed by 7,695.74% to $630.9 million in 2015, then plummeted by 51.76% to $304.4 million in 2016, then fell by 7.63% to $281.1 million in 2017.